Abstract:Purpose/Objective(s) Efficacy of immune checkpoint inhibitors (ICI) in curative head and neck squamous cell carcinoma (HNSCC) may be hampered by therapeutic ablation of tumor-draining lymphatics with standard chemoradiation (CRT). Recent emergence of neoadjuvant immunotherapy in HNSCC highlights the need for biomarkers to optimize anti-tumor immunity while eliminating locoregional microscopic disease. An elevated neutrophil-to-lymphocyte ratio (NLR) may reflect an unfavorable balance between pro-tumor inflammation and anti-tumor immunity and is associated with poor immunotherapy outcomes, yet its role as a biomarker of neoadjuvant HNSCC immunotherapy is unknown. We studied the association between NLR dynamics and prognosis in HNSCC patients treated with neoadjuvant immuno-chemotherapy followed by dose and volume response-stratified CRT. Materials/Methods 106 (71 HPV positive and 35 HPV negative) locoregionally advanced HNSCC patients prospectively enrolled in two clinical trials (NCT03107182; NCT039449150) were treated with neoadjuvant nivolumab and chemotherapy followed by dose and volume response-stratified treatment with reduced or standard CRT (including elimination of elective nodal radiation). NLRs for each patient were calculated at baseline, after neoadjuvant therapy, and 1, 3, 6, 9, and 12 months after treatment completion. NLRs at baseline and after neoadjuvant therapy were divided into quartiles, with high NLRs being the highest quartile (>3.66 and >5.63, respectively). NLR differences between reduced and standard CRT groups were analyzed by Wilcoxon ranked sum test. Overall survival (OS) and progression free survival (PFS) were analyzed by Kaplan-Meier and Cox regression methods. Results Among HPV positive patients, 37% were Stage II/III; among HPV negative patients, 97% were Stage IV (AJCC 8th ed.). 77% of all patients received reduced CRT. Median follow-up was 26.7 months. High NLRs after neoadjuvant nivolumab/chemotherapy were associated with worse OS and PFS (p=0.006 and p=0.03, respectively), while baseline high NLRs demonstrated a non-significant trend toward worse OS and PFS (p=0.16 and p=0.10, respectively). In multivariate analysis controlling for tobacco use, ECOG, stage/HPV status, treatment stratification, and PD-L1 CPS, high NLRs after neoadjuvant nivolumab/chemotherapy remained independently associated with worse OS (HR: 5.58, 95% CI: 1.51-20.56, p=0.01) and PFS (HR: 3.09, 95% CI: 1.10-8.67, p=0.03). During follow-up, NLRs were significantly lower in patients receiving reduced CRT compared to those receiving standard CRT at all time points after treatment (p<0.05). Conclusion High NLRs after neoadjuvant immuno-chemotherapy associated with worse survival in locoregionally advanced HNSCC patients. Reduced CRT led to more favorable NLRs which may enhance anti-tumor immunity after neoadjuvant immunotherapy. Further work characterizing dynamic changes in immune phenotype with neoadjuvant HNSCC immunotherapy is warranted.

Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy

Neutrophil-lymphocyte Ratio As a Prognostic Factor for Stereotactic Body Radiotherapy Treatment of Metastatic Liver Tumors.

Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy

Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors

Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis.

The Prognostic Impact of Neutrophil to Lymphocyte Ratio in Patients with Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors.

Derived Neutrophil-Lymphocyte Ratio and C-Reactive Protein As Prognostic Factors for Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.

Association of neutrophil–lymphocyte ratio with survival in peripheral early-stage non-small cell lung cancer after stereotactic body radiation therapy

Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio predicts post-stereotactic radiosurgery survival of patients with brain metastases concurrently treated with immune checkpoint inhibitors

Neutrophil-to-Lymphocyte Ratio Kinetics and Survival with Neoadjuvant Immuno-chemotherapy and Response-Stratified Chemoradiation in Locoregionally Advanced Head and Neck Cancer

Prognostic value of neutrophil-to-lymphocyte ratio change in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy

The Derived Neutrophil/Lymphocyte Ratio Predicts Poor Clinical Outcome in Early Stage Non-Small Cell Lung Patients Who Received Stereotactic Body Radiation Therapy

Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non‐small cell lung cancer undergoing stereotactic body radiotherapy

Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy

Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer

Prognostic Value of Baseline and Change in Neutrophil-to-lymphocyte Ratio for Survival in Advanced Non-Small Cell Lung Cancer Patients with Poor Performance Status Receiving PD-1 Inhibitors.

[Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].

Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy - A Single Center Experience.

Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgically Resectable Pancreatic Neuroendocrine Tumors.

Neutrophil-lymphocyte Ratio and Platelet-Lymphocyte Ratio Associations with Heart and Body Dose and Their Effects on Patient Outcomes in Locally Advanced Non-Small Cell Lung Cancer Treated with Definitive Radiotherapy.

Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation